RJA
BIOA

Raymond James & Associates’s BioAmber Inc. BIOA Stock Holding History

Raymond James & Associates’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,000
Closed -$5K – 3666
2017
Q4 		$5K Sell
13,000
-3,750
-22% -$1.78K ﹤0.01% 3399
2017
Q3 		$8K Sell
16,750
-750
-4% -$895 ﹤0.01% 3364
2017
Q2 		$45K Sell
17,500
-2,200
-11% -$5.06K ﹤0.01% 3191
2017
Q1 		$46K Buy
19,700
+900
+5% +$3.42K ﹤0.01% 3149
2016
Q4 		$103K Sell
18,800
-4,150
-18% -$19.9K ﹤0.01% 3027
2016
Q3 		$97K Buy
22,950
+1,500
+7% +$5.54K ﹤0.01% 3005
2016
Q2 		$64K Sell
21,450
-500
-2% -$1.82K ﹤0.01% 2860
2016
Q1 		$92K Buy
+21,950
New +$92.1K ﹤0.01% 2729
2015
Q2 		– Sell
-24,548
Closed -$214K – 2482
2015
Q1 		$214K Buy
+24,548
New +$216K ﹤0.01% 2309

Other funds holding BIOA

NIPH
NN Investment Partners Holdings The Hague, Netherlands $18.6B AUM 18.31% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Raymond James & Associates's BIOA Position: Q1 2018 in Review

Raymond James & Associates sold out of BioAmber Inc. (BIOA) in Q1 2018, closing a stake of 13,000 shares — an estimated $5K sold.

Raymond James & Associates first reported a position in BIOA in Q1 2015 and held it in 9 quarters. The position peaked at $214K in Q1 2015. 4 funds tracked by Wall St. Rank hold BIOA as of Q1 2018.

  • Raymond James & Associates reported no remaining BioAmber Inc. position as of Q1 2018 after selling out during the quarter.
  • Raymond James & Associates sold 13,000 BioAmber Inc. shares in Q1 2018, an estimated $5K.
  • Raymond James & Associates first reported a position in BioAmber Inc. in Q1 2015 and held it in 9 quarters.
  • Raymond James & Associates's BioAmber Inc. position peaked at $214K in Q1 2015.
  • 4 funds tracked by Wall St. Rank held BioAmber Inc. as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.